Trial design challenges when <font color="red">combining_1</font> <font color="red">medication_1</font> <font color="red">and_1</font> <font color="red">parent_1</font> <font color="red">training_1</font> in children with pervasive developmental disorders . 
<br>
<br> This paper presents the rationale for a 24-week , randomized trial designed to test whether <font color="red">risperidone_2</font> <font color="red">plus_2</font> <font color="red">structured_2</font> <font color="red">parent_2</font> <font color="red">training_2</font> would be superior to <font color="red">risperidone_2</font> <font color="red">only_1</font> on measures of noncompliance , irritability and adaptive functioning . In this model , medication reduces tantrums , aggression and self - injury ; parent training promotes improvement in noncompliance and adaptive functioning . Thus , <font color="red">medication_1</font> <font color="red">and_1</font> <font color="red">parent_1</font> <font color="red">training_1</font> target related , but separate , outcomes . At week 24 , the medication was gradually withdrawn to determine whether subjects in the combined treatment group could be managed on a lower dose or off medication without relapse . Both symptom reduction and functional improvement are important clinical treatment targets . Thus , experimental evidence on the beneficial effects of <font color="red">combining_1</font> <font color="red">pharmacotherapy_1</font> <font color="red">and_1</font> <font color="red">exportable_1</font> <font color="red">behavioral_1</font> <font color="red">interventions_1</font> is needed to guide clinical practice .